{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:37:42Z","timestamp":1777923462068,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100022502","name":"Mereo BioPharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022502","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Osteogenesis imperfecta (OI) is a rare disease characterized by low bone mass and bone fragility, associated with an increased risk of fractures, and skeletal and extra-skeletal symptoms that results in an impairment of health-related quality of life of OI patients. Since published studies on OI in Spain are limited, this study aimed to determine the epidemiology, assessed the disease burden, management and unmet needs of OI patients in Spain. Thirty-four experts in the management of patients with osteogenesis imperfecta completed two rounds of online consultation and reported real-life experience and data from Spanish hospitals. Delphi study questionnaires were based on literature review. A working group of nationally recognized clinical experts supported the development of the study questionnaires and the final validation of results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The estimated prevalence of patients diagnosed with OI in Spain is 0.56:10,000 inhabitants (95%CI: 0.54\u20130.59), which represents that, approximately, 2,669 OI patients are currently managed in Spanish hospitals. It is estimated that approximately 269 new patients would be diagnosed with OI each year in Spain, representing an estimated incidence of 0.06 (95%CI: 0.05\u20130.06) per 10,000 inhabitants per year. Clinical management of OI in Spain is performed by a range of medical specialists; however, multidisciplinary care is not fully implemented. The absence of an approved curative treatment or a treatment to reduce the clinical features of the disease remains the main unmet need.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study provides a snapshot of the current situation of patients with OI in Spain reported by clinical experts. The results provide an estimation of the epidemiology of the disease, and complement the available evidence on disease burden, clinical management, and unmet needs of these patients in Spain.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13023-024-03248-0","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T12:02:00Z","timestamp":1718712120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Current situation of osteogenesis imperfecta in Spain: results from a Delphi study"],"prefix":"10.1186","volume":"19","author":[{"given":"Bel\u00e9n","family":"Sagastizabal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c0ngels","family":"Mart\u00ednez-Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3006-7858","authenticated-orcid":false,"given":"Alicia","family":"Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Bou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"issue":"10028","key":"3248_CR1","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","volume":"387","author":"A Forlino","year":"2016","unstructured":"Forlino A, Marini JC. Osteogenesis imperfecta. Lancet. 2016;387(10028):1657\u201371.","journal-title":"Lancet"},{"key":"3248_CR2","doi-asserted-by":"publisher","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","volume":"3","author":"JC Marini","year":"2017","unstructured":"Marini JC, Forlino A, B\u00e4chinger HP, Bishop NJ, Byers PH, De PA, et al. Osteogenesis imperfecta Nature reviews Disease primers. 2017;3:17052.","journal-title":"Osteogenesis imperfecta Nature reviews Disease primers"},{"key":"3248_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1477-7525-12-54","volume":"12","author":"CL Hill","year":"2014","unstructured":"Hill CL, Baird WO, Walters SJ. Quality of life in children and adolescents with Osteogenesis Imperfecta: a qualitative interview based study. Health Qual Life Outcomes. 2014;12:54.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"3248_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-023-02643-3","volume":"18","author":"D Mc Donald","year":"2023","unstructured":"Mc Donald D, Mc Donnell T, Martin-Grace J, Mc Manus G, Crowley RK. Systematic review of health related-quality of life in adults with osteogenesis imperfecta. Orphanet J Rare Dis. 2023;18(1):36.","journal-title":"Orphanet J Rare Dis"},{"key":"3248_CR5","first-page":"349","volume":"2","author":"RB Torrent","year":"2020","unstructured":"Torrent RB. Osteog\u00e9nesis imperfecta. Protocolos diagn\u00f3sticos y terap\u00e9uticos en Pediatr\u00eda. 2020;2:349\u201359.","journal-title":"Protocolos diagn\u00f3sticos y terap\u00e9uticos en Pediatr\u00eda"},{"key":"3248_CR6","doi-asserted-by":"crossref","unstructured":"Shapiro JR. Chapter 2 - Clinical and Genetic Classification of Osteogenesis Imperfecta and Epidemiology. In: Shapiro JR, Byers PH, Glorieux FH, Sponseller PDBT-OI, editors. Osteogenesis Imperfecta: A Translational Approach to Brittle Bone Disease. San Diego: Academic Press; 2014. p. 15\u201322.","DOI":"10.1016\/B978-0-12-397165-4.00002-2"},{"issue":"12","key":"3248_CR7","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1002\/jbmr.2895","volume":"31","author":"L Folkestad","year":"2016","unstructured":"Folkestad L, Hald JD, Canudas-Romo V, Gram J, Hermann AP, Langdahl B, et al. Mortality and Causes of Death in Patients With Osteogenesis Imperfecta: A Register-Based Nationwide Cohort Study. J Bone Miner Res. 2016;31(12):2159\u201366.","journal-title":"J Bone Miner Res"},{"key":"3248_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.869604","volume":"13","author":"S Storoni","year":"2022","unstructured":"Storoni S, Treurniet S, Maugeri A, Pals G, van den Aardweg JG, van der Pas SL, et al. Prevalence and Hospital Admissions in Patients With Osteogenesis Imperfecta in The Netherlands: A Nationwide Registry Study. Front Endocrinol. 2022;13: 869604.","journal-title":"Front Endocrinol"},{"issue":"5","key":"3248_CR9","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/ajmg.a.35327","volume":"158A","author":"DA Stevenson","year":"2012","unstructured":"Stevenson DA, Carey JC, Byrne JLB, Srisukhumbowornchai S, Feldkamp ML. Analysis of skeletal dysplasias in the Utah population. Am J Med Genet A. 2012;158A(5):1046\u201354.","journal-title":"Am J Med Genet A"},{"issue":"8","key":"3248_CR10","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/ejhg.2015.81","volume":"23","author":"K Lindahl","year":"2015","unstructured":"Lindahl K, \u00c5str\u00f6m E, Rubin C-J, Grigelioniene G, Malmgren B, Ljunggren \u00d6, et al. Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta. European journal of human genetics\u202f: EJHG. 2015;23(8):1042\u201350.","journal-title":"European journal of human genetics : EJHG"},{"key":"3248_CR11","unstructured":"Steiner RD, Basel D. COL1A1\/2 Osteogenesis Imperfecta. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, et al., editors. GeneReviews. Seattle (WA): University of Washington; 1993."},{"key":"3248_CR12","doi-asserted-by":"publisher","unstructured":"Darb\u00e0 J, Mars\u00e0 A. Hospital incidence, management and direct cost of osteogenesis imperfecta in Spain: a retrospective database analysis. J Med Econ. 2020;23(12):1435\u201340. Available from: https:\/\/doi.org\/10.1080\/13696998.2020.1834402.","DOI":"10.1080\/13696998.2020.1834402"},{"key":"3248_CR13","first-page":"1","volume":"91","author":"S Gimeno-martos","year":"2017","unstructured":"Gimeno-martos S, P\u00e9rez-Riera C, Guardiola-Vilarroig S, Cavero-Carbonell C. Epidemiology of Imperfect Osteogenesis\u202f: a Rare Disease in the Valencia Region. 2017;91:1\u201310.","journal-title":"Epidemiology of Imperfect Osteogenesis : a Rare Disease in the Valencia Region"},{"key":"3248_CR14","unstructured":"Asociaci\u00f3n Nacional Huesos de Cristal (AHUCE). Pronostico e incidencia de Osteog\u00e9nesis imperfecta [Internet]. [cited 2023 May 17]. Available from: http:\/\/www.ahuce.org\/Osteogenesis_imperfecta\/Diagnostico_y_Manifestaciones_de_la_Osteogenesis\/Pronostico_e_incidencia_de_Osteogenesis_imperfecta.aspx."},{"key":"3248_CR15","unstructured":"Ministerio de Sanidad. Informe ReeR 2022: Situaci\u00f3n de las Enfermedades Raras en Espa\u00f1a. State Register of Rare Diseases. 2022. [Internet]. [cited 2023 May 17]. Available from: https:\/\/www.sanidad.gob.es\/areas\/alertasEmergenciasSanitarias\/vigilancia\/docs\/InformeEpidemiologicoAnual_2023_ACCESIBLE.pdf."},{"key":"3248_CR16","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3389\/fendo.2019.00924","volume":"10","author":"SH Ralston","year":"2019","unstructured":"Ralston SH, Gaston MS. Management of Osteogenesis Imperfecta. Front Endocrinol. 2019;10:924.","journal-title":"Front Endocrinol"},{"issue":"4","key":"3248_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.4055\/cios20060","volume":"12","author":"T-J Cho","year":"2020","unstructured":"Cho T-J, Ko JM, Kim H, Shin H-I, Yoo WJ, Shin CH. Management of Osteogenesis Imperfecta: A Multidisciplinary Comprehensive Approach. Clin Orthop Surg. 2020;12(4):417\u201329.","journal-title":"Clin Orthop Surg"},{"key":"3248_CR18","doi-asserted-by":"publisher","unstructured":"Mueller B, Engelbert R, Baratta-Ziska F, Bartels B, Blanc N, Brizola E, et al. Consensus statement on physical rehabilitation in children and adolescents with osteogenesis imperfecta. Orphanet J Rare Dis. 2018;13(1):158. Available from: https:\/\/doi.org\/10.1186\/s13023-018-0905-4.","DOI":"10.1186\/s13023-018-0905-4"},{"issue":"1","key":"3248_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11914-016-0299-y","volume":"14","author":"IH Thomas","year":"2016","unstructured":"Thomas IH, DiMeglio LA. Advances in the Classification and Treatment of Osteogenesis Imperfecta. Curr Osteoporos Rep. 2016;14(1):1\u20139.","journal-title":"Curr Osteoporos Rep"},{"key":"3248_CR20","unstructured":"Guerrero-Fern\u00e1ndez J, Casado IG, Bonis ACB, Mart\u00edn NI, Palma CM, Fresno LS, et al. Manual de diagn\u00f3stico y terap\u00e9utica en Endocrinolog\u00eda Pedi\u00e1trica. 1st ed. Ergon; 2018."},{"key":"3248_CR21","doi-asserted-by":"crossref","unstructured":"Riancho JA, Peris P, Gonz\u00e1lez-Mac\u00edas J, P\u00e9rez-Castrill\u00f3n JL. Gu\u00edas de pr\u00e1ctica cl\u00ednica en la osteoporosis postmenop\u00e1usica, glucocorticoidea y del var\u00f3n (actualizaci\u00f3n 2022) . Vol. 14, Revista de Osteoporosis y Metabolismo Mineral. scieloes ; 2022. p. 13\u201333.","DOI":"10.4321\/S1889-836X2022000100003"},{"key":"3248_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.115048","volume":"129","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Makras P, Tournis S, Anastasilakis AD. Off-label uses of denosumab in metabolic bone diseases. Bone. 2019;129: 115048.","journal-title":"Bone"},{"issue":"5","key":"3248_CR23","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/jbmr.2410","volume":"30","author":"JD Hald","year":"2015","unstructured":"Hald JD, Evangelou E, Langdahl BL, Ralston SH. Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials. J Bone Min Res. 2015;30(5):929\u201333.","journal-title":"J Bone Min Res"},{"key":"3248_CR24","doi-asserted-by":"publisher","unstructured":"Liu W, Lee B, Nagamani SCS, Nicol L, Rauch F, Rush ET, et al. Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta. J Clin Endocrinol Metabol. 2023;108(7):1787\u201396. Available from: https:\/\/doi.org\/10.1210\/clinem\/dgad035.","DOI":"10.1210\/clinem\/dgad035"},{"key":"3248_CR25","doi-asserted-by":"crossref","unstructured":"Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2016;10(10):CD005088.","DOI":"10.1002\/14651858.CD005088.pub4"},{"key":"3248_CR26","doi-asserted-by":"publisher","first-page":"43399","DOI":"10.1038\/srep43399","volume":"7","author":"S Ma","year":"2017","unstructured":"Ma S, Goh EL, Jin A, Bhattacharya R, Boughton OR, Patel B, et al. Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties. Sci Rep. 2017;7:43399.","journal-title":"Sci Rep"},{"key":"3248_CR27","doi-asserted-by":"crossref","unstructured":"Barrett D, Heale R. What are Delphi studies? Evidence Based Nursing [Internet]. 2020;23(3):68 LP \u2013 69. Available from: http:\/\/ebn.bmj.com\/content\/23\/3\/68.abstract.","DOI":"10.1136\/ebnurs-2020-103303"},{"key":"3248_CR28","doi-asserted-by":"crossref","unstructured":"Meshkat B, Cowman S, Gethin G, Ryan K, Wiley M, Brick A, et al. Using an e-Delphi technique in achieving consensus across disciplines for developing best practice in day surgery in Ireland Using an e-Delphi technique in achieving consensus across disciplines for developing best practice in day surgery in Ireland.\u00a0J\u00a0Hosp\u00a0Adm.\u00a02014;0\u20138.","DOI":"10.5430\/jha.v3n4p1"},{"issue":"4","key":"3248_CR29","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.eujim.2015.07.002","volume":"7","author":"EG Trevelyan","year":"2015","unstructured":"Trevelyan EG, Robinson PN. Delphi methodology in health research: how to do it? Eur J Integrat Med. 2015;7(4):423\u20138.","journal-title":"Eur J Integrat Med"},{"issue":"4","key":"3248_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5430\/jha.v3n4p1","volume":"3","author":"B Meshkat","year":"2014","unstructured":"Meshkat B, Cowman S, Gethin G, Ryan K, Wiley M, Brick A, et al. Using an e-Delphi technique in achieving consensus across disciplines for developing best practice in day surgery in Ireland. J Hosp Admin. 2014;3(4):1.","journal-title":"J Hosp Admin"},{"issue":"1","key":"3248_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4103\/aca.ACA_157_18","volume":"22","author":"P Mishra","year":"2019","unstructured":"Mishra P, Pandey CM, Singh U, Gupta A, Sahu C, Keshri A. Descriptive statistics and normality tests for statistical data. Ann Card Anaesth. 2019;22(1):67\u201372.","journal-title":"Ann Card Anaesth"},{"key":"3248_CR32","unstructured":"INE. Instituto Nacional de Estad\u00edstica [Internet]. [cited 2023 May 16]. Available from: https:\/\/www.ine.es\/."},{"issue":"1","key":"3248_CR33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1186\/s12891-022-05433-3","volume":"23","author":"S Barlow","year":"2022","unstructured":"Barlow S, Dove L, Jaggi A, Keen R, Bubbear J. The prevalence of musculoskeletal pain and therapy needs in adults with Osteogenesis Imperfecta (OI) a cross-sectional analysis. BMC Musculoskelet Disord. 2022;23(1):485.","journal-title":"BMC Musculoskelet Disord"},{"issue":"40","key":"3248_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030256","volume":"101","author":"R Mu\u00f1oz Cort\u00e9s","year":"2022","unstructured":"Mu\u00f1oz Cort\u00e9s R, Soriano Pastor JF, Monsalve DV. Chronic pain in adults with osteogenesis imperfecta and its relationship to appraisal, coping, and quality of life: A cross-sectional study. Medicine. 2022;101(40): e30256.","journal-title":"Medicine"},{"issue":"3","key":"3248_CR35","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/AJP.0000000000000395","volume":"33","author":"T Nghiem","year":"2017","unstructured":"Nghiem T, Louli J, Treherne SC, Anderson CE, Tsimicalis A, Lalloo C, et al. Pain Experiences of Children and Adolescents With Osteogenesis Imperfecta: An Integrative Review. Clin J Pain. 2017;33(3):271\u201380.","journal-title":"Clin J Pain"},{"key":"3248_CR36","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/s12913-014-0489-1","volume":"14","author":"MJ Dogba","year":"2014","unstructured":"Dogba MJ, Rauch F, Wong T, Ruck J, Glorieux FH, Bedos C. From pediatric to adult care: strategic evaluation of a transition program for patients with osteogenesis imperfecta. BMC Health Serv Res. 2014;14:489.","journal-title":"BMC Health Serv Res"},{"issue":"Suppl 2","key":"3248_CR37","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s12325-019-01174-3","volume":"37","author":"C G\u00f3mez-Alonso","year":"2020","unstructured":"G\u00f3mez-Alonso C. Paediatric Metabolic Bone Disease: A Lifetime Ahead. Adv Ther. 2020;37(Suppl 2):38\u201346.","journal-title":"Adv Ther"},{"issue":"8","key":"3248_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10174","volume":"3","author":"JT Tauer","year":"2019","unstructured":"Tauer JT, Robinson M-E, Rauch F. Osteogenesis Imperfecta: New Perspectives From Clinical and Translational Research. JBMR plus. 2019;3(8): e10174.","journal-title":"JBMR plus"},{"issue":"4","key":"3248_CR39","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1530\/EJE-20-0299","volume":"183","author":"R Marom","year":"2020","unstructured":"Marom R, Rabenhorst BM, Morello R. Osteogenesis imperfecta: an update on clinical features and therapies. Eur J Endocrinol. 2020;183(4):R95-106.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"3248_CR40","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.gastrohep.2023.06.005","volume":"47","author":"R Aller","year":"2024","unstructured":"Aller R, Calleja JL, Crespo J, Romero-G\u00f3mez M, Turnes J, Benmarzouk-Hidalgo OJ, et al. Advanced fibrosis associated with non-alcoholic steatohepatitis (NASH) in Spain: results of a Delphi study. Gastroenterol Hepatol. 2024;47(4):337\u201346.","journal-title":"Gastroenterol Hepatol"},{"issue":"2","key":"3248_CR41","first-page":"75","volume":"68","author":"A Gil-Nagel","year":"2019","unstructured":"Gil-Nagel A, Sanchez-Carpintero R, San Antonio V, Mistry A, Barker G, Shepherd J, et al. Ascertaining the epidemiology, patient flow and disease management for Dravet syndrome in Spain. Rev Neurol. 2019;68(2):75\u201381.","journal-title":"Rev Neurol"},{"key":"3248_CR42","doi-asserted-by":"crossref","unstructured":"Calleja-Panero JL, Andrade RJ, al. E. Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts. Rev Esp Enferm Dig. 2020;112(10):778\u201383. Available from: https:\/\/online.reed.es\/DOI\/PDF\/Articulo_6895.pdf.","DOI":"10.17235\/reed.2020.6895\/2020"},{"key":"3248_CR43","unstructured":"Par\u00e9s A, Albillos A, Andrade RJ, Berenguer M, Crespo J, Romero-G\u00f3mez M, et al. Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. Rev Esp Enferm Dig. 2018;110(10):641\u20139."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03248-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03248-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03248-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T03:01:52Z","timestamp":1732244512000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03248-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3248"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03248-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,18]]},"assertion":[{"value":"15 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BS, IC, AFM and RB received fees from Mereo Biopharma for their participation in the study. JC is an employee of Mereo Biopharma. AP and AG are employees of Omakase Consulting S.L. Omakase Consulting S.L. received funding from Mereo Biopharma to conduct this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"239"}}